-
Je něco špatně v tomto záznamu ?
Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies
L. Hejnova, Z. Drastichova, A. Boroš, J. Hrdlicka, M. Behuliak, J. Neckar, J. Zicha, J. Novotny
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2014
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The consequences at the molecular level and the mechanisms involved in a possible cardioprotective effect of antihypertensive treatment are not yet fully understood. Here, the efficacy of pyridostigmine (PYR) and trandolapril (TRA) as antihypertensive and antihypertrophic agents was investigated and compared in hypertensive SHR and normotensive WKY rats. In parallel, we investigated the effects of these drugs on myocardial β-adrenergic and cholinergic signaling pathways and protein expression profiles. METHODS: Age-matched male SHR and WKY rats were chronically (8 weeks) treated with PYR or TRA in drinking water. Blood pressure (BP) and heart rate (HR) were monitored telemetrically prior to tissue sampling for biochemical analysis. Baroreceptor reflex sensitivity (BRS) and methylatropine HR response as a measure of vagal tone were evaluated in separate groups of animals. RESULTS: PYR slightly lowered BP and HR in SHR rats during the dark phase of the day, while TRA effectively reduced BP during the light and dark phases without affecting HR. PYR enhanced BRS and improved vagal tone. There were no significant alterations in myocardial β-adrenergic and cholinergic signaling, with the exception of decreased forskolin-stimulated adenylyl cyclase (AC) activity in SHR rats, which was restored by TRA. Proteomic analysis revealed numerous differences induced by both treatments. Notable were changes in TGFβ-related signaling pathways as well as proteins involved in modifying hemodynamic parameters and cardiac hypertrophy. CONCLUSIONS: PYR is able to slightly decrease BP and HR in SHR rats but effectively increase BRS through vagal potentiation. The specific differences in protein expression profiles in rat myocardium induced by treatment with PYR and TRA reflect different mechanisms of action of these two agents at the molecular level.
Department of Physiology Faculty of Science Charles University Prague Czechia
Institute of Physiology Czech Academy of Sciences Prague Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002479
- 003
- CZ-PrNML
- 005
- 20250618083302.0
- 007
- ta
- 008
- 250117e20240916sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fcvm.2024.1390547 $2 doi
- 035 __
- $a (PubMed)39355349
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hejnova, Lucie $u Department of Physiology, Faculty of Science, Charles University, Prague, Czechia
- 245 10
- $a Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies / $c L. Hejnova, Z. Drastichova, A. Boroš, J. Hrdlicka, M. Behuliak, J. Neckar, J. Zicha, J. Novotny
- 520 9_
- $a BACKGROUND: The consequences at the molecular level and the mechanisms involved in a possible cardioprotective effect of antihypertensive treatment are not yet fully understood. Here, the efficacy of pyridostigmine (PYR) and trandolapril (TRA) as antihypertensive and antihypertrophic agents was investigated and compared in hypertensive SHR and normotensive WKY rats. In parallel, we investigated the effects of these drugs on myocardial β-adrenergic and cholinergic signaling pathways and protein expression profiles. METHODS: Age-matched male SHR and WKY rats were chronically (8 weeks) treated with PYR or TRA in drinking water. Blood pressure (BP) and heart rate (HR) were monitored telemetrically prior to tissue sampling for biochemical analysis. Baroreceptor reflex sensitivity (BRS) and methylatropine HR response as a measure of vagal tone were evaluated in separate groups of animals. RESULTS: PYR slightly lowered BP and HR in SHR rats during the dark phase of the day, while TRA effectively reduced BP during the light and dark phases without affecting HR. PYR enhanced BRS and improved vagal tone. There were no significant alterations in myocardial β-adrenergic and cholinergic signaling, with the exception of decreased forskolin-stimulated adenylyl cyclase (AC) activity in SHR rats, which was restored by TRA. Proteomic analysis revealed numerous differences induced by both treatments. Notable were changes in TGFβ-related signaling pathways as well as proteins involved in modifying hemodynamic parameters and cardiac hypertrophy. CONCLUSIONS: PYR is able to slightly decrease BP and HR in SHR rats but effectively increase BRS through vagal potentiation. The specific differences in protein expression profiles in rat myocardium induced by treatment with PYR and TRA reflect different mechanisms of action of these two agents at the molecular level.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Drastichova, Zdenka $u Department of Physiology, Faculty of Science, Charles University, Prague, Czechia
- 700 1_
- $a Boroš, Almos $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Hrdlicka, Jaroslav $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Behuliak, Michal $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia $7 xx0196023
- 700 1_
- $a Neckar, Jan $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Zicha, Josef $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Novotny, Jiri $u Department of Physiology, Faculty of Science, Charles University, Prague, Czechia
- 773 0_
- $w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 11 (20240916), s. 1390547
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39355349 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250618083253 $b ABA008
- 999 __
- $a ok $b bmc $g 2254596 $s 1238482
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 11 $c - $d 1390547 $e 20240916 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
- LZP __
- $a Pubmed-20250117